Integrative Treatment and Wellness Tips for Hyperparathyroidism

Learn about the latest approaches to integrative treatment for hyperparathyroidism that can support your recovery.

Abstract

Welcome to our educational series. I’m Dr. Alex Jimenez, and I’m honored to share my insights and the latest research on complex endocrine conditions. In this comprehensive post, we will explore primary hyperparathyroidism, a condition characterized by an overproduction of parathyroid hormone (PTH) that, while common, is often misunderstood by both patients and practitioners. This condition leads to elevated blood calcium levels, a state known as hypercalcemia, which can have wide-ranging effects on the body, from bone fragility to kidney stones and neurocognitive symptoms. We will journey through the nuanced landscape of its diagnosis, from asymptomatic discoveries on routine blood work to more overt, symptomatic presentations. This post is designed to be a definitive guide, taking you on an easy-to-understand journey through the fundamental roles of calcium, vitamin D, and parathyroid hormone, and the modern, evidence-based research that shapes our clinical decision-making. We will delve into the specific diagnostic workup, including essential laboratory tests like PTH, vitamin D, and 24-hour urine calcium, as well as crucial imaging studies such as DEXA scans and neck ultrasounds. We will compare the clinical presentations of hyperparathyroidism across different populations, discuss the critical indications for surgical intervention versus watchful observation, and explore medical management strategies for patients who are not surgical candidates. A significant portion of this discussion will be dedicated to real-world case studies from my practice, illustrating the diverse ways this condition can manifest and the various treatment pathways we can follow. We will also delve into how our unique, multidisciplinary clinic model at Injury Medical Clinic, P.A., integrates integrative chiropractic care, medical oversight by our esteemed Medical Director, Dr. Maria Guadalupe Cardenas, MD, functional medicine, and comprehensive rehabilitation to provide a holistic and patient-centered approach to care. This post aims to empower you with the knowledge to understand this condition, its physiological underpinnings, and the collaborative strategies we employ for optimal patient outcomes.

Our Collaborative and Integrative Practice: A Multidisciplinary Approach to Patient Care

At the core of our practice, Injury Medical Clinic, P.A. (also known as Mission Plaza Injury Medical Clinic), is a philosophy of collaborative, patient-centered care. I am Dr. Alex Jimenez, and my credentials—DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST—reflect a deep commitment to a multifaceted approach to health and wellness. My personal journey and extensive training across multiple disciplines—as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), Board-Certified Family Nurse Practitioner (FNP-BC), Certified Functional Medicine Practitioner (CFMP), IFM Certified Practitioner (IFMCP), Certified in Autoimmune & Thyroid Neurology (ATN), and Certified in Chiropractic Spinal Trauma (CCST)—have instilled in me a deep appreciation for the body’s interconnected systems. This perspective is the foundation of our practice philosophy: we treat the whole person, not just a set of symptoms or a lab value.

However, true integrative care thrives on the synergy of diverse expertise. This is why I am privileged to work alongside Dr. Maria Guadalupe Cardenas, MD. As a Board Certified Internist with an NPI of #1164426749 and Texas MD License #J2933, Dr. Cardenas brings over 40 years of profound clinical experience in internal medicine to our practice. She serves as our Medical Director and Collaborative Physician, providing essential medical oversight and guidance. This multidisciplinary structure, where a chiropractor and a medical doctor collaborate closely, is a cornerstone of modern integrative and injury care clinics. It allows us to bridge the gap between different medical philosophies and offer a continuum of care that is both comprehensive and cohesive, ensuring that our patients in El Paso, Texas, receive the most comprehensive and well-rounded care possible.

Together, Dr. Cardenas and I, along with our dedicated team of professionals, have built a practice that seamlessly blends:

• Medical Oversight (Dr. Cardenas, MD): Dr. Cardenas provides the crucial medical framework for our diagnostic and treatment protocols, ensuring all plans are medically sound, safe, and appropriate, especially for complex conditions like hyperparathyroidism. She manages the medical aspects—interpreting complex lab work, prescribing medications like calcimimetics or bisphosphonates when necessary, and making referrals for surgical evaluation.
• Integrative Chiropractic Care (Dr. Jimenez, DC): I focus on the biomechanical integrity of the body, particularly the spine and nervous system, which can be affected by the systemic consequences of metabolic disorders.
• Functional Medicine: We employ functional medicine principles to conduct a deep dive into each patient’s unique biochemistry, genetics, and lifestyle. This allows us to create highly personalized treatment plans that address the underlying drivers of disease.
• Personal Injury Care & Rehabilitation: We are also equipped to manage complex personal injury cases, offering comprehensive rehabilitation programs designed to restore function and improve quality of life.

This integrated model is particularly powerful when managing complex endocrine disorders like hyperparathyroidism. While an endocrinologist or surgeon might focus on the parathyroid glands themselves, our team looks at the broader picture. We consider how high calcium levels and hormonal imbalances affect bone density, muscle function, neurological health, and overall well-being. This allows us to create a truly holistic treatment plan that supports the patient before, during, and after conventional medical or surgical interventions, optimizing their journey back to health.

Integrating Chiropractic Care into Endocrine Health Management

You might wonder how integrative chiropractic care fits into the management of an endocrine disorder like hyperparathyroidism. The connection lies in our holistic view of the body as an interconnected system. The endocrine system, which governs our hormones, is intricately linked with the nervous system. The spine, as the central conduit for the nervous system, plays a crucial role in maintaining proper communication between the brain and the rest of the body, including the glands of the endocrine system.

My role as a chiropractor within our team involves:

• Neuromechanical Assessment: Identifying and correcting vertebral subluxations or biomechanical dysfunctions that may interfere with nerve signaling. While this is not a direct treatment for the parathyroid glands, optimizing nervous system function can help the body better adapt to the systemic stress caused by hormonal imbalances.
• Musculoskeletal Symptom Management: Patients with hyperparathyroidism often experience muscle aches, joint pain, and fatigue. One of the primary targets of excess PTH is the skeleton. Chronic bone resorption leads to pain, stiffness, and an increased risk of fractures. Our chiropractic care focuses on improving spinal alignment, reducing joint restrictions, and alleviating musculoskeletal pain. Gentle, specific adjustments, soft tissue therapies, and targeted rehabilitation exercises can provide significant relief from these musculoskeletal symptoms, improving a patient’s overall quality of life. At the same time, their underlying endocrine condition is being managed. This directly addresses the “bones” aspect of hyperparathyroidism.
• Functional Medicine Integration: My functional medicine training allows me to look at the bigger picture. We assess nutritional status, particularly Vitamin D, which has a direct and critical relationship with parathyroid hormone and calcium. We also examine lifestyle factors, stress levels, and gastrointestinal health, all of which can influence endocrine function and overall well-being. This comprehensive approach ensures we are not just chasing symptoms but addressing the foundational pillars of health.

By combining Dr. Cardenas’s medical direction with our comprehensive chiropractic, rehabilitative, and functional medicine protocols, we provide a safety net of care that supports the patient through every stage of their journey with hyperparathyroidism. This ensures they are not only biochemically “cured” or managed but are also functionally stronger, more resilient, and better educated to maintain their long-term health.

Understanding the Parathyroid Glands: The Body’s Calcium Regulators

To begin our journey into hyperparathyroidism, we must first understand the anatomy and function of the parathyroid glands themselves. Most individuals have four parathyroid glands, which are tiny, pea-sized structures located in the neck, nestled behind the much larger thyroid gland. Typically, there are two superior glands and two inferior glands, one pair on each side of the trachea. Despite their small size, these glands play a monumental role in our physiology by acting as the body’s primary regulators of calcium.

The history of diagnosing hyperparathyroidism is a fascinating medical detective story. The first definitive diagnosis was made back in 1926 by Dr. Eugene Dubois. His patient, a seaman named Captain Charles Martel, suffered from a devastating series of health issues, primarily affecting his skeletal system. He endured multiple surgeries for severe bone deterioration and fractures, yet his condition continued to worsen. It was only during his seventh operation that surgeons discovered the root cause: a parathyroid adenoma, a benign tumor on one of his parathyroid glands that was relentlessly overproducing parathyroid hormone.

Captain Martel’s case is a classic, albeit extreme, example of the devastating impact of untreated primary hyperparathyroidism. His illness was marked by severe bone pain and recurrent urinary calculi, or kidney stones, which are hallmark complications of chronic hypercalcemia. Tragically, the complications arising from his condition eventually led to his death. If you were to search for images of Captain Martel online, you would find photographs documenting the dramatic and debilitating changes to his skeletal structure over the course of his illness. His story serves as a powerful reminder of why early and accurate diagnosis is so crucial.

The Three Pillars of Parathyroid Health: Calcium, Vitamin D, and PTH

To truly grasp hyperparathyroidism, we must conduct a deep dive into the three key players in this physiological drama: calcium, vitamin D, and parathyroid hormone (PTH). These three elements are intricately linked in a complex dance that governs bone health, neuromuscular function, and overall metabolic stability.

Calcium: More Than Just a Mineral for Bones

Calcium is the most abundant mineral in the human body. While approximately 99% of it is stored in our bones and teeth, providing structural integrity, the remaining 1% circulating in our blood is where the real action happens. This small fraction of circulating calcium is so critical that the body has developed a powerful and redundant regulatory system to keep its levels within a very tight range.

The roles of this circulating calcium are vast and vital:

• Neuromuscular Function: Calcium ions are essential for nerve impulse transmission and muscle contraction. Proper calcium levels ensure that our nerves fire correctly and our muscles, including our heart muscle, contract and relax as they should.
• Cardiac Function: The rhythmic contraction of the heart is exquisitely dependent on the flow of calcium ions into and out of cardiac muscle cells. Imbalances can lead to arrhythmias and other cardiac issues.
• Blood Clotting: Calcium is a critical cofactor in the coagulation cascade, the complex series of steps that allows our blood to clot when we are injured, preventing excessive bleeding.

Understanding Calcium Measurements: Total vs. Ionized

When we measure calcium in the blood, the standard lab test reports the total serum calcium. It’s important to understand that this total calcium exists in two main forms:

1. Bound Calcium: About 40-45% of calcium is bound to proteins, primarily albumin. This form is inactive.
2. Ionized Calcium: About 50-55% of calcium is “free” or unbound. This is the biologically active form that performs all the vital functions mentioned above, and it is this form that our body, including the parathyroid glands, actually senses and responds to.

This distinction is clinically significant. Because a large portion of calcium is bound to albumin, a patient’s albumin level can affect their total calcium measurement. For instance, in a patient with low albumin (hypoalbuminemia), which can occur in states of malnutrition, liver disease, or chronic illness, more calcium will be in the free, ionized form, and less will be protein-bound. This can lead to a total serum calcium level that appears normal or even low, masking a potential underlying hypercalcemia. This phenomenon is known as pseudohypocalcemia.

To account for this, we can calculate a “corrected calcium” level using a standard formula that adjusts the total calcium based on the patient’s albumin level. However, a more direct and accurate method is to measure the ionized calcium. This test specifically quantifies the free, biologically active calcium in the blood, bypassing the influence of albumin levels altogether. Getting an accurate ionized calcium measurement can be tricky. The sample must be handled meticulously by the laboratory—it needs to be collected anaerobically (without exposure to air) and processed quickly to prevent changes in blood pH, which can alter ionized calcium levels. While this test may be more critical for acutely ill, hospitalized patients with acid-base disturbances, it also holds significant value in the outpatient setting.

Emerging research has highlighted a fascinating connection: there is a strong, direct linear relationship between the ionized calcium level and the size of a parathyroid adenoma. This correlation is significantly stronger than the one observed between total serum calcium and adenoma size. In my clinical practice, this means that a higher ionized calcium level not only confirms the presence of biologically significant hypercalcemia but also suggests a higher probability of finding a larger, more easily identifiable adenoma during imaging and surgery. This makes ionized calcium a powerful tool in our diagnostic arsenal.

Vitamin D: The “Sunshine Vitamin” and Its Crucial Role

Vitamin D is not just a vitamin; it’s a potent prohormone. This fat-soluble compound is unique because our bodies can synthesize it through sun exposure, and it also plays a direct role in calcium metabolism. Its primary function is to facilitate the absorption of calcium from our diet.

The Journey of Vitamin D in the Body

We acquire vitamin D from two main sources:

1. Sunlight Exposure: Our skin contains a precursor to vitamin D. When exposed to ultraviolet B (UVB) radiation from the sun, this precursor is converted into vitamin D3 (cholecalciferol).
2. Dietary Intake: We can also consume vitamin D through foods and supplements.

Once vitamin D enters the body, whether from the skin or the gut, it is biologically inert. It must undergo a two-step activation process to become the active hormone:

1. First Hydroxylation (in the Liver): The Liver converts vitaminLiverto 25-hLiveryvitamin D [25(OH)D]. This is the major circulating form of vitamin D and is the form we measure in the blood to assess a person’s vitamin D status.
2. Second Hydroxylation (in the Kidneys): The kidneys then convert 25(OH)D into 1,25-dihydroxyvitamin D [1,25(OH)2D], also known as calcitriol. This is the fully active, hormonal form of vitamin D. This final activation step is tightly regulated by parathyroid hormone (PTH). When PTH levels are high, it stimulates the kidneys to produce more calcitriol.

The active form, calcitriol, then exerts its primary effect on the intestines, dramatically increasing the efficiency of calcium and phosphorus absorption from the food we eat. This ensures that the body has an adequate supply of calcium to deposit into bones and maintain normal blood levels. Without sufficient vitamin D, we can only absorb about 10-15% of the calcium from our diet. With adequate vitamin D, this absorption can increase to 30-40%.

Vitamin D2 vs. Vitamin D3: What’s the Difference?

When you look at supplements or prescriptions for vitamin D, you will encounter two forms:

• Vitamin D3 (Cholecalciferol): This is the form that is naturally synthesized in our skin upon sun exposure. It is also found in animal-based food sources.

• • Dietary Sources: Excellent sources include oily fish like wild-caught salmon (which can provide 300-1,000 IU per 4-ounce serving), cod liver oil (a classic, potent source providing 400-1,000 IU per teaspoon), and foods fortified with vitamin D3, such as milk and some cereals.
  • Supplements: Most over-the-counter vitamin D supplements are in the D3 form, available in doses ranging from 400 IU to 10,000 IU per capsule.

• Vitamin D2 (Ergocalciferol): This form is derived from plant sources, primarily fungi and yeast.

• • Dietary Sources: Sun-dried mushrooms can be a good source of D2. Egg yolks contain a small amount (about 20 IU per yolk), but one would need to consume a very large quantity to get a significant dose.
  • Prescription Form: The high-dose, prescription-strength vitamin D (typically 50,000 IU taken once a week) is usually vitamin D2.

For many years, these two forms were considered equivalent. However, a growing body of research suggests that vitamin D3 is more potent and effective at raising and maintaining blood levels of 25(OH)D. It appears to have a higher binding affinity for the vitamin D receptors in our cells and is more similar to the form our bodies naturally produce. For this reason, in my functional medicine practice, I almost exclusively recommend vitamin D3 for supplementation to ensure optimal efficacy.

Parathyroid Hormone (PTH): The Master Regulator

Parathyroid hormone, as we’ve discussed, is the hormone secreted by the four small parathyroid glands in the neck. Its sole purpose is to increase blood calcium levels. When the calcium-sensing receptors on the surface of the parathyroid glands detect a drop in serum calcium, they trigger the release of PTH.

PTH acts on three primary target organs to raise blood calcium:

1. Bones: PTH stimulates osteoclasts, the cells responsible for breaking down bone tissue. This process, called bone resorption, releases stored calcium and phosphorus from the skeleton into the bloodstream. In the short term, this is a normal physiological process. However, in a state of chronic PTH excess, such as in primary hyperparathyroidism, this leads to a continuous loss of bone mass, resulting in osteopenia, osteoporosis, and an increased risk of fractures.
2. Kidneys: PTH has two major effects on the kidneys.

• • It increases the reabsorption of calcium, preventing it from being lost in the urine. It essentially tells the kidneys to “hold on” to calcium.
  • It promotes the excretion of phosphorus. This is why patients with primary hyperparathyroidism often have low or low-normal serum phosphorus levels.
  • Critically, as mentioned before, it stimulates the final activation step of vitamin D, converting 25(OH)D to the active hormone calcitriol [1,25(OH)2D].

• Intestines (Indirectly): By stimulating the production of active vitamin D (calcitriol), PTH indirectly enhances the absorption of calcium from the food we eat in the small intestine.

The net result of these actions is a potent and rapid increase in serum calcium levels. When calcium levels return to normal, they provide negative feedback to the parathyroid glands, shutting off further PTH secretion.

• Hyperparathyroidism: When the parathyroid glands produce too much PTH, it leads to hypercalcemia (high blood calcium).
• Hypoparathyroidism: Conversely, when the glands produce too little PTH (usually after neck surgery), it results in hypocalcemia (low blood calcium).

This intricate system underscores why we must always evaluate calcium, vitamin D, and PTH together. They are inseparable components of a single regulatory axis, and viewing any one of them in isolation will lead to an incomplete and potentially incorrect clinical picture.

Understanding Hypercalcemia: The First Clue

In my clinical practice, a patient’s journey toward a diagnosis of hyperparathyroidism often begins with a routine blood test. We run a Comprehensive Metabolic Panel (CMP) for many of our patients as part of a baseline health assessment or to investigate non-specific symptoms like fatigue or body aches. One of the key markers on this panel is serum calcium. When I see an elevated calcium level, it immediately signals the need for a more thorough investigation. This condition, known as hypercalcemia, is the primary biochemical signpost pointing toward a potential issue with the parathyroid glands.

The relationship between calcium and parathyroid hormone (PTH) is the cornerstone of understanding parathyroid function. This relationship is best visualized as a feedback loop, where the level of one directly influences the level of the other. We can illustrate this with a simple graph.

Imagine a graph with the serum calcium level on the horizontal (X) axis and the parathyroid hormone (PTH) level on the vertical (Y) axis. In a healthy individual, this relationship is inverse:

• When blood calcium levels are low, the parathyroid glands are stimulated to release more PTH.
• When blood calcium levels are high, the parathyroid glands are signaled to release less PTH.

This finely tuned system ensures that calcium levels remain within a very narrow, healthy range. However, in disease states, this relationship breaks down.

• Primary Hyperparathyroidism: This is the condition we are focusing on today. In this scenario, one or more of the parathyroid glands become overactive and produce PTH autonomously, regardless of the blood calcium level. On our graph, this would be represented in the top-right quadrant. We see a high calcium level coexisting with a high or inappropriately high PTH. This is the classic biochemical signature of primary hyperparathyroidism. The feedback loop is broken; the parathyroid gland is no longer listening to the body’s signals to stop producing the hormone.
• Hypercalcemia of Other Causes: What if a patient presents with high calcium, but their PTH level is low or suppressed? This would be found in the bottom-right quadrant of our graph. A high calcium level should suppress PTH production. If it does, this tells us the parathyroid glands are functioning correctly and are not the source of the problem. This is when we must look for other causes of the high calcium.

Differential Diagnosis for Elevated Calcium

It’s a critical error to jump to a single conclusion. As a functional medicine practitioner, my first step is always to build a comprehensive differential diagnosis. Hyperparathyroidism is a common cause of high calcium, but it is by no means the only one. We must systematically rule out other potential culprits to ensure an accurate diagnosis and appropriate treatment plan. When faced with a hypercalcemic patient, I consider a wide range of possibilities, known as non-PTH-mediated hypercalcemia.

• Hypercalcemia of Malignancy: This is one of the most serious considerations. Certain cancers, particularly those of the lung, breast, and kidney, as well as multiple myeloma, can produce a substance called parathyroid hormone-related protein (PTHrP). This protein mimics the action of PTH, leading to the release of calcium from the bones and causing hypercalcemia. In other cases, cancer can metastasize to the bone, directly destroying bone tissue and releasing calcium into the bloodstream. Typically, in hypercalcemia of malignancy, the patient’s own PTH level will be suppressed (very low), which is a key distinguishing feature from primary hyperparathyroidism.
• Vitamin D or Vitamin A Toxicity: Vitamins are essential for health, but in excessive amounts, they can become toxic.

• • Vitamin D Toxicity: Vitamin D promotes calcium absorption from the gut. When a person takes excessively high doses of vitamin D supplements, it can lead to dangerously high levels of calcium in the blood. This is why I always ask patients to bring in all of their supplements—bottles in hand—so we can review the exact dosages.
  • Vitamin A Toxicity: High levels of vitamin A can also increase bone resorption, the process where bone is broken down, releasing calcium into the blood. This is less common but remains an important consideration in the differential diagnosis.

• Milk-Alkali Syndrome: This syndrome has seen a resurgence with the widespread use of over-the-counter calcium supplements, particularly calcium carbonate, for indigestion and osteoporosis prevention. A triad of hypercalcemia, metabolic alkalosis, and acute kidney injury characterizes it. The underlying cause is the ingestion of large amounts of calcium and absorbable alkali.

• • A Clinical Example: We recently had a compelling case in our clinic that perfectly illustrates this. A patient presented with a significantly high calcium level on her labs. During our detailed consultation, I made it a point to ask specifically about over-the-counter supplements. She initially didn’t mention anything she considered a “medication,” but when I probed further about things for indigestion or heartburn, she admitted to taking Tums. When I asked for a specific quantity—a crucial step in functional medicine—she revealed she was taking thirty Tums per day. Each Tums tablet contains calcium carbonate, and at that volume, she was consuming a massive amount of calcium, which was the direct cause of her hypercalcemia. This highlights the absolute necessity of taking a detailed, quantified patient history. Discontinuing the Tums and educating her on proper hydration and alternative heartburn remedies resolved her hypercalcemia without the need for an extensive endocrine workup.

• Prolonged Immobilization: Patients who are bedridden for long periods, such as after a severe injury or major surgery, can develop hypercalcemia. The lack of mechanical stress on the bones from weight-bearing activities leads to increased bone resorption and a release of calcium into the bloodstream.
• Other Endocrine and Systemic Conditions:

• • Hyperthyroidism: An overactive thyroid gland can increase bone turnover, leading to mild hypercalcemia.
  • Adrenal Insufficiency (Addison’s Disease): This condition can cause hypercalcemia through volume contraction (dehydration) and decreased renal excretion of calcium.
  • Granulomatous Diseases: Conditions like sarcoidosis and tuberculosis (TB) involve the formation of granulomas, which are clusters of inflammatory cells. The macrophages within these granulomas can independently produce an enzyme (1-alpha-hydroxylase) that converts inactive vitamin D to its active form, calcitriol. This leads to increased calcium absorption from the gut and subsequent hypercalcemia, even with normal PTH levels.

• Medications: As we will discuss in more detail, certain medications, like thiazide diuretics and lithium, are well-known causes of hypercalcemia.
• Total Parenteral Nutrition (TPN): Patients receiving all their nutrition intravenously can sometimes develop hypercalcemia if the calcium content in their TPN solution is not appropriately managed.

The Symptoms of Hypercalcemia: From Silent to Severe

One of the most challenging aspects of diagnosing primary hyperparathyroidism is that its presentation can be incredibly varied. Many patients, especially in the early stages, are completely asymptomatic. The elevated calcium is often discovered incidentally on routine blood work ordered for another reason. When I call a patient to discuss a newly found high calcium level, the most common response I hear is, “But I feel fine!”

The classic mnemonic “bones, stones, abdominal groans, and psychic moans” captures the array of potential symptoms. Still, the onset and severity are generally related to both the degree and the acuity of the calcium elevation.

• Mild Hypercalcemia (e.g., calcium levels in the 10.5-11.5 mg/dL range): Many patients with calcium levels in this range may not notice any overt symptoms. However, upon careful questioning, they might admit to subtle issues like fatigue, mild cognitive fogginess, or a general sense of not feeling their best. These vague symptoms are often dismissed as normal signs of aging or stress.
• Moderate Hypercalcemia (e.g., calcium levels > 11.5 mg/dL): As calcium levels climb, symptoms become more pronounced. The classic triad of polyuria (frequent urination), polydipsia (excessive thirst), and nocturia (waking up at night to urinate) often begins to appear. High calcium levels impair the kidneys’ ability to concentrate urine, leading to the loss of large volumes of water. This dehydration, in turn, triggers intense thirst. These symptoms are very similar to those of new-onset diabetes, which can sometimes cause diagnostic confusion if a comprehensive metabolic panel is not performed.
• Severe Hypercalcemia (e.g., calcium levels > 12 mg/dL): At these levels, symptoms can become much more severe and even life-threatening. Patients may experience:

• • Gastrointestinal Symptoms: Nausea, vomiting, constipation, and abdominal pain are common. High calcium slows down gut motility, leading to severe constipation.
  • Neurological Symptoms: Confusion, lethargy, depression, and significant mental status changes can occur. In extreme cases, a patient can become obtunded or comatose.
  • Cardiovascular Symptoms: Hypercalcemia can affect the heart’s electrical conduction, potentially leading to a shortened QT interval on an EKG and an increased risk of arrhythmias.
  • Renal Symptoms: The persistent polyuria and dehydration can lead to a pre-renal acute kidney injury (AKI), where the kidneys begin to fail due to a lack of adequate blood flow.

It is a common clinical observation that patients with calcium levels in the high 10s often report feeling relatively well. In contrast, those with levels consistently above 11.0 or 11.5 mg/dL are more likely to be symptomatic. The goal of early diagnosis and treatment is to intervene before the more severe and debilitating symptoms develop, preventing long-term complications like osteoporosis, kidney stones, and chronic kidney disease.

Clinical Pearls for Evaluating Hypercalcemia: A Step-by-Step Guide

Navigating the diagnostic process for hypercalcemia requires a logical, stepwise approach. Rushing to conclusions can lead to unnecessary tests and patient anxiety. Here is the protocol I follow in my practice, which aligns with evidence-based guidelines.

Step 1: Confirm the Finding

If routine labs show an elevated serum calcium, the very first thing I do is re-check it. Lab errors can happen. A patient might be dehydrated at the time of the blood draw, or there could be a technical issue with the sample (e.g., prolonged tourniquet time). I typically have the patient return for a repeat blood draw, ensuring they are well-hydrated beforehand.

• If the repeat calcium is normal: For a one-time, unconfirmed elevation, we can often monitor. I would tell the patient that we will keep an eye on it during their next routine check-up. If it appears again on a future lab test, then we will proceed with a full investigation. But for a single, non-reproducible result, aggressive workup is usually not warranted.
• If the repeat calcium is still elevated, this confirms a true state of hypercalcemia, and we must proceed to the next diagnostic step.

Step 2: Add the Parathyroid Hormone (PTH) Level

Once we have confirmed persistent hypercalcemia, the next and most critical test is to measure the intact parathyroid hormone (PTH) level. This single test is the key to differentiating between PTH-mediated hypercalcemia (like primary hyperparathyroidism) and non-PTH-mediated hypercalcemia (like malignancy or vitamin D toxicity).

• Elevated or Inappropriately Normal PTH: If the calcium is high and the PTH is also high, this is the classic picture of primary hyperparathyroidism. An “inappropriately normal” PTH is also highly suggestive. Logically, if blood calcium is high, the parathyroid glands should sense this and shut down PTH production, leading to a very low or suppressed PTH level. If the PTH level is in the “normal” range despite high calcium, it is still behaving inappropriately—it’s not responding to the negative feedback loop. This scenario is also treated as indicative of primary hyperparathyroidism.
• Low or Suppressed PTH: If the calcium is high but the PTH level is low, this tells us the parathyroid glands are functioning correctly—they are trying to stop PTH production in response to the high calcium. The hypercalcemia is therefore being caused by something else. This is when we would aggressively investigate for other causes, such as malignancy (ordering a PTHrP level), vitamin D toxicity, or granulomatous disease.

Primary Hyperparathyroidism: The Classic Presentation

When the diagnostic workup points to an elevated calcium level accompanied by an elevated (or inappropriately normal) PTH level, we arrive at the diagnosis of primary hyperparathyroidism. Historically, this was known as a disease of “bones, stones, abdominal groans, and psychic moans.” This memorable phrase described the classic, symptomatic presentation before the 1970s.

• Bones: Patients would present with severe bone pain and fractures due to extensive bone resorption caused by excess PTH. This severe form of bone disease is called osteitis fibrosa cystica.
• Stones: High levels of calcium in the urine (hypercalciuria) would lead to the formation of painful kidney stones (nephrolithiasis).
• Abdominal Groans: Hypercalcemia can affect the gastrointestinal system, causing constipation, nausea, indigestion, and even peptic ulcers.
• Psychic Moans: The central nervous system is also sensitive to high calcium levels. Patients would report fatigue, depression, confusion, memory loss, and general malaise.

Today, this full-blown symptomatic presentation is much less common. Why? Because of the advent of routine biochemical screening. The vast majority of cases of primary hyperparathyroidism I diagnose in my practice are asymptomatic. We discover them incidentally through a routine CMP that reveals hypercalcemia. The patient often feels relatively well and is surprised by the diagnosis. This shift from a symptomatic to an asymptomatic disease has fundamentally changed how we approach and manage it.

Other Causes of Elevated PTH and Calcium

While primary hyperparathyroidism is the most common cause, there are a few other, rarer scenarios that can present with both high calcium and high PTH. It is crucial to consider these to avoid misdiagnosis.

Medication-Induced Hyperparathyroidism

Two key medications can mimic the biochemical profile of primary hyperparathyroidism:

1. Thiazide Diuretics (e.g., Hydrochlorothiazide – HCTZ): These are commonly prescribed for high blood pressure. Thiazide diuretics work in the kidney’s distal tubule, where they decrease the renal excretion of calcium. This causes more calcium to be retained in the blood, leading to mild hypercalcemia. This chronic, low-level hypercalcemia can then mildly stimulate the parathyroid glands, resulting in a slightly elevated PTH. If I have a patient with this biochemical profile who is taking a thiazide, my first move is often to collaborate with their primary care provider or cardiologist to see if the diuretic can be temporarily held or switched to a different class of antihypertensive. We would then re-check the calcium and PTH levels after a washout period to see if they normalize.
2. Lithium: This medication, used as a mood stabilizer in bipolar disorder, has a direct effect on the parathyroid glands. Lithium alters the “set-point” of the calcium-sensing receptors on the parathyroid cells. It makes the glands less sensitive to calcium, meaning a higher level of calcium is required to suppress PTH secretion. Essentially, the glands think the calcium level is lower than it actually is and continue to produce PTH. This results in both hypercalcemia and elevated PTH. Managing this requires close collaboration with the patient’s psychiatrist, as abruptly stopping lithium is often not an option.

Familial Hypocalciuric Hypercalcemia (FHH)

This is a very important, though rare, condition to distinguish from primary hyperparathyroidism because their management is completely different.

• Genetic Basis: FHH is an autosomal dominant genetic disorder. It is caused by a mutation in the gene for the calcium-sensing receptor (CaSR) found on parathyroid cells and in the kidneys.
• Pathophysiology: This mutation makes the receptors throughout the body less sensitive to calcium. The parathyroid glands continue to secrete PTH despite high blood calcium, and the kidneys are “tricked” into reabsorbing more calcium from the urine, thinking the body needs to conserve it.
• Key Distinguishing Feature: The hallmark of FHH is low urine calcium. Despite having high blood calcium, these patients excrete very little calcium in their urine. This is in stark contrast to primary hyperparathyroidism, where high PTH levels typically lead to high urine calcium.
• Diagnosis: We diagnose FHH by collecting a 24-hour urine sample to measure calcium and creatinine. We then calculate the calcium-to-creatinine clearance ratio (CCCR).

• • In primary hyperparathyroidism, the CCCR is typically greater than 0.02.
  • In FHH, the CCCR is characteristically less than 0.01.

• Why it Matters: Patients with FHH are generally asymptomatic and do not suffer from the complications of hyperparathyroidism (like osteoporosis or kidney stones). Critically, they do not benefit from parathyroid surgery. Removing the parathyroid glands will not cure their condition, as the underlying issue is a systemic receptor defect. Identifying FHH saves the patient from an unnecessary and ineffective operation.

Familial Hyperparathyroidism Syndromes

If I diagnose primary hyperparathyroidism in a younger patient, particularly someone under the age of 30, I become suspicious of a familial syndrome. These patients should be evaluated for Multiple Endocrine Neoplasia (MEN) syndromes, types 1 and 2A. These are genetic disorders that predispose individuals to tumors in various endocrine glands. In these cases, the hyperparathyroidism is often caused by hyperplasia (enlargement) of all four parathyroid glands, rather than a single adenoma. A referral for genetic counseling and testing is essential for these patients and their families.

Classifying Hyperparathyroidism: Primary, Secondary, and Tertiary

To fully grasp the pathophysiology, it’s helpful to understand the different classifications of hyperparathyroidism. The following chart, adapted from Quest Diagnostics, provides a clear and concise overview that I often use to educate my patients. It helps to visualize how the interplay between calcium and PTH levels points toward a specific diagnosis.

Calcium Level	Parathyroid Hormone (PTH) Level	Likely Diagnosis
High or Normal-High	High or Inappropriately Normal	Primary Hyperparathyroidism
Normal or Low	High	Secondary Hyperparathyroidism
High	High (markedly)	Tertiary Hyperparathyroidism

Let’s break these down:

• Primary Hyperparathyroidism: This is the focus of our discussion. The problem originates within the parathyroid glands themselves. One or more glands develop a benign tumor (an adenoma) or become hyperplastic, causing them to autonomously produce excessive amounts of PTH, regardless of the body’s calcium levels. This drives up blood calcium.
• Secondary Hyperparathyroidism: In this case, the parathyroid glands are actually functioning correctly. They are producing high levels of PTH in response to a chronic state of hypocalcemia (low blood calcium) or a disruption in calcium homeostasis. The glands are working overtime to try to raise the low calcium levels back to normal. The most common causes are:

• • Chronic Kidney Disease (CKD): This is the leading cause of secondary hyperparathyroidism. Diseased kidneys are unable to convert vitamin D into its active form, which impairs calcium absorption from the gut. Additionally, they fail to excrete phosphate, leading to hyperphosphatemia. High phosphate binds to calcium in the blood, lowering free calcium levels. Both mechanisms result in chronic hypocalcemia, which relentlessly stimulates the parathyroid glands to produce more PTH.
  • Severe Vitamin D Deficiency: A lack of vitamin D leads to poor dietary calcium absorption, causing hypocalcemia and a compensatory rise in PTH.
  • Malabsorption Syndromes: Conditions like celiac disease or Crohn’s disease can impair the absorption of both calcium and vitamin D, leading to secondary hyperparathyroidism.

• Tertiary Hyperparathyroidism: This is a late-stage complication that arises from long-standing, severe secondary hyperparathyroidism, most often in patients with end-stage renal disease. After years of chronic stimulation, the parathyroid glands undergo hyperplastic transformation and become autonomous. They grow so large and numerous that they start to pump out massive amounts of PTH, regardless of the calcium level. Even if the original cause of the hypocalcemia is corrected (for example, through a kidney transplant), the glands continue to overproduce PTH. At this stage, the patient develops hypercalcemia on top of a very high PTH level. Tertiary hyperparathyroidism often requires surgical removal of the parathyroid glands.

A Deeper Look at Normocalcemic Primary Hyperparathyroidism

There is a fascinating and sometimes diagnostically challenging subset of patients who have what is known as Normocalcemic Primary Hyperparathyroidism (NPHPT). These individuals have consistently elevated PTH levels, but their total and ionized calcium levels remain within the normal range.

Diagnosing NPHPT requires careful exclusion of all causes of secondary hyperparathyroidism. The official diagnostic criteria are:

1. Normal adjusted total calcium and normal ionized calcium on multiple occasions.
2. Elevated PTH level, confirmed at least twice over a three- to six-month period.
3. Exclusion of all other causes that could be elevating PTH, specifically:

• • Vitamin D deficiency: The 25-hydroxy vitamin D level must be above 30 ng/mL.
  • Renal insufficiency: The estimated Glomerular Filtration Rate (eGFR) must be greater than 60 mL/min/1.73m².
  • Medications: The patient must not be taking lithium or thiazide diuretics.
  • Malabsorption issues: No history of conditions like celiac or bariatric surgery.
  • Other metabolic bone diseases: No evidence ofPaget’ss disease or other conditions affecting bone metabolism.

NPHPT is considered an early form of primary hyperparathyroidism. Over time, a significant portion of these patients will progress to develop overt hypercalcemia. They require close monitoring, and the decision to intervene is based on whether they develop symptoms or complications, such as declining bone density or kidney stones, even while their calcium remains “normal.”

Understanding Primary Hyperparathyroidism: To Treat or to Watch?

One of the most frequent challenges my patients face when diagnosed with primary hyperparathyroidism is the confusion that surrounds it. Often, the condition is discovered incidentally during routine lab work, revealing an elevated calcium level in someone who feels perfectly fine. They present with absolutely no symptoms. Receiving this information and then being told that surgery might be the best course of action for a problem they can’t even feel can be daunting. This is precisely where careful, evidence-based patient education becomes paramount. We are now in an era where we can follow these patients over time, observe the natural history of their condition, and make more informed decisions.

To illustrate this point, I often refer to a pivotal study that provides great clarity on the “watchful waiting” approach.

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”- Video

Insights from a Ten-Year Randomized Controlled Trial

I frequently share the findings of a study conducted by Pretorius and colleagues, published in 2020, because it directly addresses the question of surgery versus observation for asymptomatic patients. The research, titled “Effect of parathyroidectomy on quality of life in asymptomatic primary hyperparathyroidism: a 10-year follow-up of a prospective randomized controlled trial,” provides invaluable long-term data.

• Study Design: The researchers took 192 patients who were diagnosed with asymptomatic primary hyperparathyroidism. These individuals were then randomly assigned, in a one-to-one ratio, to either undergo a parathyroidectomy (surgical removal of the overactive parathyroid gland) or to be part of an observation group.
• Quality of Life Assessment: To measure the impact on well-being, the study used two validated quality-of-life scales: the Short Form-36 Health Survey (SF-36) and the Comprehensive Psychopathological Rating Scale (CPRS). These assessments were administered at the beginning of the study (baseline) and then at 2, 5, and 10 years.
• Biochemical Outcomes: As expected, the surgical group achieved a biochemical cure. Their calcium and parathyroid hormone levels returned to the normal range after the procedure. In stark contrast, the observation group’s calcium and parathyroid hormone levels remained persistently elevated throughout the ten years.
• Quality of Life Findings: Here is where the results become particularly interesting. When analyzing the SF-36, only one of the eight measured scales—vitality—showed a statistically significant improvement in the surgical group compared to the observation group. For the CPRS, both groups actually improved similarly over the decade.
• The Ten-Year Conclusion: The ultimate conclusion drawn by the researchers after a full decade of follow-up was profound: for asymptomatic patients, parathyroid surgery does not necessarily lead to a significant improvement in overall quality of life, and conversely, observation does not lead to a worsening of quality of life.

I like to let my patients sit with this information. It demonstrates that, for many, watching and waiting is a perfectly safe and valid option. It empowers them, reducing the anxiety that can come with a new diagnosis and the pressure to rush into an invasive procedure. Of course, this approach is only appropriate as long as we carefully monitor for specific indications that would signal a worsening of the condition and necessitate intervention. But having the space and time to observe is often a reassuring path for patients.

Hyperparathyroidism: A Tale of Two Cities

The clinical presentation of primary hyperparathyroidism is not uniform across the globe. It is a fascinating example of how environmental factors, particularly nutritional status, can dramatically influence the manifestation of a disease. A study I often reference to highlight this is a comparative analysis that I call “The Tale of Two Cities.” This research, published in 2000 by a team of authors including Silverberg and Bilezikian, compared the clinical features of primary hyperparathyroidism in patients from the United States with those from Beijing, China.

The study included one hundred subjects from each location, and the differences they found were striking, painting two very different pictures of the same underlying condition.

The Western Presentation: Asymptomatic and Subtle

In the United States and other Western countries, the classic presentation of primary hyperparathyroidism has evolved over the past several decades.

• Demographics: It is typically a disease of older adults, often discovered in postmenopausal women, with the diagnosis occurring about ten years after menopause.
• Biochemistry: The hypercalcemia is usually mild. The average serum calcium level in the U.S. patients in this study was 10.4 mg/dL. Their average parathyroid hormone (PTH) level was elevated, but moderately so, at around 118 pg/mL.
• Vitamin D Status: A key factor is the patient’s Vitamin D level. The average Vitamin D level in the U.S. cohort was 21 ng/mL. While this is on the lower end of the optimal range, it is significantly higher than what was seen in the Chinese cohort. This relative Vitamin D sufficiency is a crucial reason for the milder disease presentation.
• Skeletal and Renal Manifestations: The severe, classic signs of the disease are now rarely seen.

• • Bone Disease: Obvious radiological evidence of bone disease, such as osteitis fibrosa cystica (the “brown tumors” and cysts caused by excessive bone resorption), is extremely uncommon. Skeletal involvement is now almost exclusively detected through the subtle changes measured by bone densitometry (DEXA scan), revealing osteopenia or osteoporosis.
  • Kidney Stones: The incidence of kidney stone disease (nephrolithiasis) has dramatically decreased. In the 1940s, up to 60% of patients with hyperparathyroidism had kidney stones. Today, that estimate is closer to 15-20%.

In essence, in the U.S., we are typically dealing with a subtle, asymptomatic disease found through routine screening in a population that is generally not severely Vitamin D deficient.

The Eastern Presentation: Symptomatic and Severe

The picture from Beijing, China, at the time of the study, was dramatically different and more closely resembled the historical descriptions of hyperparathyroidism from the pre-screening era.

• Demographics: The disease presented much earlier in life. The average age of the patients in the Beijing cohort was only 37 years old.
• Biochemistry: The biochemical abnormalities were far more severe.

• • The average serum calcium was significantly higher, at 0 mg/dL.
  • The parathyroid hormone values were astonishingly high, often over twenty times the upper limit of normal.
  • Vitamin D Deficiency: This is the most critical difference. The average Vitamin D level was profoundly low, at a mere 8 ng/mL, indicating severe deficiency.

• Skeletal and Renal Manifestations: With such severe biochemical derangements, the clinical consequences were profound and overt.

• • Bone Disease: Radiologic evidence of osteitis fibrosa cystica was evident in a staggering 60% of the patients. Almost all patients had developed osteoporosis.
  • Pathological Fractures: The severe bone disease led to fragility. Thirty-five percent (35%) of the patients in China had suffered pathological fractures—fractures that occur from minimal or no trauma—most commonly in the femur or humerus.
  • Kidney Stones: Kidney stones were also highly prevalent, affecting 42% of the patients.
  • Constitutional Symptoms: Unlike the asymptomatic U.S. patients, weakness and fatigue were almost universally present and often debilitating.

This “Tale of Two Cities” powerfully illustrates that primary hyperparathyroidism is a disease spectrum. The patient’s Vitamin D status profoundly influences the severity. In regions where Vitamin D deficiency is endemic, the parathyroid glands must work much harder to maintain calcium balance, leading to more aggressive gland growth (larger adenomas) and much more severe clinical consequences. This is why, in my practice, assessing and correcting Vitamin D levels is a fundamental and non-negotiable step in managing any patient with elevated calcium or PTH. It provides crucial context for the severity of their condition and is a key target for therapeutic intervention.

The Comprehensive Diagnostic Workup for Primary Hyperparathyroidism

Once the initial labs suggest primary hyperparathyroidism, a comprehensive workup is necessary to confirm the diagnosis, assess the severity of the disease, and determine the best course of action. This workup involves a specific set of laboratory tests and imaging studies.

Essential Laboratory Tests

When I am working up a patient for primary hyperparathyroidism, I order the following panel of tests:

1. Comprehensive Metabolic Panel (CMP): This is foundational. It reconfirms the serum calcium level and provides crucial information about renal function (BUN, creatinine, and eGFR) and the albumin level (for correcting calcium if needed).
2. Intact Parathyroid Hormone (PTH): As discussed, this is essential to confirm the diagnosis alongside high calcium.
3. 25-Hydroxy Vitamin D: This is a critical test. Vitamin D deficiency is extremely common and can coexist with primary hyperparathyroidism. If the patient has both, the vitamin D deficiency can “mask” the full extent of their hypercalcemia. When we replete their vitamin D, calcium absorption improves, and their serum calcium level may rise significantly, revealing the true severity of the disease. It’s also vital to rule out vitamin D deficiency as a cause of secondary hyperparathyroidism. My goal is to get this level comfortably above 30 ng/mL.
4. Serum Phosphorus: In primary hyperparathyroidism, high PTH levels cause the kidneys to waste phosphate. Therefore, a low or low-normal phosphorus level is a common and supportive finding.
5. 24-Hour Urine Collection for Calcium and Creatinine: This test is indispensable for two reasons. First, it helps to definitively rule out Familial Hypocalciuric Hypercalcemia (FHH) by allowing us to calculate the calcium-to-creatinine clearance ratio. Second, the total amount of calcium excreted in 24 hours is a key factor in determining the need for surgery. High levels of urine calcium (hypercalciuria) significantly increase the risk of kidney stone formation and represent one of the primary indications for surgical intervention.

Essential Imaging Tests

The imaging studies we order are not for diagnosing the condition (that is done biochemically) but for assessing the end-organ damage caused by the excess PTH and for pre-operative planning.

1. DEXA Scan (Dual-Energy X-ray Absorptiometry): This is a specialized X-ray that measures bone mineral density (BMD). It is essential in every patient with primary hyperparathyroidism. PTH’s primary effect is on cortical bone (the dense, outer shell of bones), more so than on trabecular bone (the spongy, inner part). Therefore, the DEXA scan must include not only the standard sites—the lumbar spine and hip—but also the distal one-third of the radius (the forearm). This site is rich in cortical bone and is often the first and most severely affected location. A diagnosis of osteoporosis (a T-score of -2.5 or lower at any of these three sites) is a major indication for surgery.

• • Advanced DEXA Metrics: If available, I also request a Vertebral Fracture Assessment (VFA) and a Trabecular Bone Score (TBS).

• • • VFA is a lateral image of the spine taken on the DEXA machine that can detect asymptomatic vertebral compression fractures, which are another clear indication for surgery.
    • TBS is a textural analysis of the lumbar spine image that provides an indirect measure of bone microarchitecture quality. A low TBS indicates fragile bone structure and an increased fracture risk, even if the BMD is not in the osteoporotic range.

• Renal Ultrasound: We order a kidney ultrasound to look for evidence of kidney stones (nephrolithiasis) or calcium deposits within the kidney tissue itself (nephrocalcinosis). Even if a patient has never had the classic pain of passing a stone, they may have “silent” stones visible on ultrasound. The presence of any stone or calcification is another strong indication for surgery.
• Pre-operative Localization Scans (Neck Ultrasound and Sestamibi Scan): These scans are not used for diagnosis but are vital for the surgeon to plan the operation. The goal is to identify which of the four parathyroid glands is the culprit.

• • Neck Ultrasound: A high-resolution ultrasound performed by an experienced radiologist can often visualize an enlarged parathyroid adenoma in the neck.
  • Sestamibi Scan (Parathyroid Scintigraphy): This is a nuclear medicine scan. The patient is injected with a small amount of a radioactive tracer (technetium-99m sestamibi) that is preferentially taken up by overactive parathyroid tissue. A special camera then scans the neck and chest to see where the tracer has accumulated, pinpointing the location of the adenoma. Modern techniques often combine this with a CT scan (SPECT/CT) for precise 3D localization.
  • Surgeon’s Preference: The choice of which localization study to order often depends on the preference of the surgeon to whom I am referring the patient. Identifying the abnormal gland pre-operatively allows the surgeon to perform a minimally invasive parathyroidectomy, targeting only the single bad gland, which results in a smaller incision, faster recovery, and lower risk.

Indications for Surgery: Does This Patient Need Parathyroidectomy?

Having journeyed through research and real-world clinical scenarios, let’s distill the key principles of managing primary hyperparathyroidism. When you see that high calcium, your diagnostic and management pathway becomes clearer if you think about it through the lens of one central question: “Does this patient need surgery?” Framing it this way helps guide the tests you need to order.

Surgery (parathyroidectomy) is the only definitive cure for primary hyperparathyroidism. Once the workup is complete, I sit down with the patient and review the findings against the internationally accepted guidelines for surgical intervention. A patient is considered a candidate for surgery if they meet any one of the following criteria:

• Age: Age less than 50 years. The reasoning is that younger individuals have a longer lifetime ahead of them to suffer the cumulative negative effects of hypercalcemia on their bones, kidneys, and cardiovascular system.
• Serum Calcium Level: Serum calcium concentration more than 1.0 mg/dL above the upper limit of the normal range. I take the time to explain this carefully to patients. I show them their lab report, point out their value, and then point to the lab’s reference range. This empowers them to understand their own results, even if they have labs done at different facilities with slightly different normal ranges.
• Kidney Involvement:

• • A documented history of kidney stones (by imaging or passage), whether symptomatic or discovered incidentally.
  • A significant reduction in kidney function, with an eGFR less than 60 mL/min/1.73m². This indicates that the hypercalcemia is already damaging the kidneys.
  • 24-hour urine calcium greater than 400 mg/day. This indicates a high risk for stone formation. (Note: some earlier guidelines used lower numbers, like 250 in women and 350 in men, but the trend is toward the 400 mg threshold as a stronger indicator).

• Bone Involvement:

• • A T-score of -2.5 or lower at the lumbar spine, total hip, femoral neck, or distal 1/3 radius on a DEXA scan (a diagnosis of osteoporosis).
  • The presence of a vertebral fragility fracture (often asymptomatic and found on VFA or spine X-ray).

• Symptomatic Disease: While many patients are asymptomatic, classic, attributable symptoms of hypercalcemia (like the “bones, stones, abdominal groans, and psychic moans”) can also be an indication, though this is often a more subjective criterion.

Even if a patient does not meet any of these formal criteria, a surgical consult can still be offered. If a patient is symptomatic (experiencing fatigue, “brain fog,” or aches and pains) and wishes to explore the possibility of a cure, a referral to a surgeon is a perfectly appropriate and patient-centered decision.

The Surgical Solution and Its Benefits

When I refer a patient for surgery, my most important piece of advice is to find a high-volume, experienced parathyroid surgeon. This cannot be overstated. Parathyroid surgery is a delicate, nuanced procedure. A general surgeon who only performs a few of these a year may not have the same level of expertise as an endocrine surgeon who specializes in it.

• A Personal Anecdote: Early in my career, I referred several patients who I felt were clear surgical candidates to a local general surgeon. Almost every time, he would send a note back stating he felt surgery was not indicated. After a discussion, it became clear that this particular surgery was not one he was comfortable with or enjoyed performing. It was a preference issue. After that, I established relationships with surgeons who had a dedicated interest and expertise in parathyroid surgery. The outcomes for my patients improved dramatically. Finding the right surgeon is paramount.

The Surgical Procedure and Outcomes

The surgery, called a parathyroidectomy, typically involves a small incision in the neck. In over 80-90% of cases of primary hyperparathyroidism, the cause is a single benign parathyroid adenoma. The surgeon uses the pre-operative localization scans and often an intra-operative gamma probe to find the adenoma and remove it. They will often measure the patient’s PTH level in the operating room. A rapid drop in the PTH level after the gland is removed confirms that they have found and excised the source of the problem.

• Cure Rate: In the hands of an experienced surgeon, parathyroidectomy achieves a biochemical cure (normalizing calcium and PTH levels) in approximately 98% of patients. It is a very safe and highly effective procedure.
• Rare Pathologies: Multi-gland hyperplasia occurs in about 15% of cases and may require the removal of 3.5 glands. Parathyroid carcinoma (cancer) is exceedingly rare, occurring in less than 1% of all cases. I always make sure to share this statistic with patients to alleviate their fears, as the word “adenoma” or “tumor” often immediately brings cancer to mind.

The Benefits of Surgery

What can a patient expect after a successful parathyroidectomy? The benefits are significant and multi-systemic.

• Biochemical Normalization: Calcium, PTH, vitamin D, and urinary calcium levels all return to normal.
• Improvement in Neurocognitive Symptoms: Many patients report a dramatic improvement in energy levels, concentration, and mood. The “brain fog” often lifts within weeks or months.
• Decreased Kidney Stone Risk: The risk of forming new kidney stones decreases significantly.
• Stabilization of Renal Function: The decline in kidney function often stabilizes or even slightly improves.
• Consistent Improvement in Bone Density: This is one of the most reliable and well-documented benefits. Over the years following surgery, patients experience a significant increase in their bone mineral density, particularly at the lumbar spine and hip. This directly translates to a reduced risk of fractures.
• Cardiovascular Disease and Mortality: It is important to note that current high-quality evidence does not show a significant change in the rates of cardiovascular disease or overall mortality after surgery. The primary benefits are related to skeletal and renal health and quality of life.

To help patients better understand the appearance of enlarged parathyroid tissue, here are practical examples drawn from surgical specimens shared by Dr. Holly Raoshfort, an excellent endocrine surgeon I have worked with.

A single enlarged parathyroid adenoma removed at surgery is often many times larger than a normal gland (typically no bigger than a grain of rice). In one representative case, the adenoma measured several centimeters and was readily visible and palpable once exposed.

In another example, two hyperplastic parathyroid glands were removed; each was distinctly enlarged compared with the remaining normal glands, reflecting the diffuse overgrowth seen in parathyroid hyperplasia rather than a solitary adenoma.

Medical Management: The Non-Surgical Pathway

What if a patient does not meet the criteria for surgery, is not a good surgical candidate due to other health issues, or declines the procedure? In these cases, we move to a plan of active surveillance and medical management. The goals of non-surgical treatment are twofold:

1. Reduce the serum calcium level to prevent symptoms of hypercalcemia.
2. Preserve or increase bone density to decrease fracture risk.

Guidelines for Active Surveillance

For my patients with asymptomatic primary hyperparathyroidism who are being managed medically, I follow a strict monitoring protocol:

• Office Visits: I see them at least twice a year.
• Annual Lab Work:

• • Serum calcium
  • PTH
  • 25-hydroxy vitamin D
  • CMP to monitor creatinine/eGFR

• DEXA Scan: A bone density scan is repeated every one to two years to monitor for any decline in bone mass.
• Vitamin D Sufficiency: We ensure their vitamin D level is maintained at a healthy level, typically above 30 ng/mL, to prevent exacerbating the hyperparathyroidism.

Pharmacological Treatment

If a patient’s calcium level is persistently high and they are not a surgical candidate, we can use medication. Medical management with drugs like cinacalcet or bisphosphonates can control the calcium levels, but they do not fix the underlying problem of the overactive gland. Only removing the adenoma (or hyperplastic glands) can provide a permanent cure.

• Cinacalcet (Sensipar): This is the primary medication used for this purpose. Cinacalcet is a calcimimetic. It works by binding to the calcium-sensing receptors on the parathyroid gland and “tricking” the gland into thinking that calcium levels are higher than they are. This increases the gland’s sensitivity to calcium and causes it to reduce PTH secretion.

• • Dosing: The starting dose is typically 30 mg twice a day. The dose is then titrated every two to four weeks upwards based on the patient’s calcium levels, with a maximum dose of 90 mg twice a day. The goal is to bring the calcium level down into the normal range.
  • Caution: Cinacalcet should be used with caution in patients with a history of seizures or conditions that can prolong the QT interval on an EKG.

• Bisphosphonates: If the patient has coexisting osteoporosis, medications to treat coexisting bone loss are essential. Bisphosphonates (e.g., alendronate, risedronate) are anti-resorptive agents. They work by inhibiting osteoclasts, the cells that break down bone. By slowing bone resorption, they can help increase bone density and also cause a modest reduction in serum calcium levels.

The Role of Integrative and Functional Medicine

Beyond the conventional medical and surgical treatments, our integrative approach offers a powerful layer of supportive care that addresses the whole person. Chronic hypercalcemia and elevated PTH can lead to muscle weakness (proximal myopathy), bone pain, and an increased risk of fractures. Our chiropractic care and functional medicine guidance focus on:

• Musculoskeletal Health: We design specific, safe, weight-bearing exercise programs to help stimulate bone formation and improve muscle strength and balance, reducing the risk of falls and fractures. We also use non-pharmacological techniques like manual therapy and myofascial release to address the “aches and groans” associated with the condition.
• Functional Nutrition and Lifestyle Support: Using functional medicine principles, we conduct a thorough analysis of the patient’s diet and lifestyle.

• • Vitamin D and Cofactors: We don’t just replete vitamin D; we ensure the patient also has adequate levels of its key cofactors, such as magnesium, vitamin K2, and zinc, which are essential for proper calcium metabolism and bone health. Magnesium, for example, is required for the activation of vitamin D. Vitamin K2 helps direct calcium into the bones and away from soft tissues like arteries.
  • Anti-Inflammatory Diet: We often recommend an anti-inflammatory, whole-foods-based diet to reduce the systemic inflammation that can exacerbate symptoms and contribute to chronic disease.
  • Hydration: This is non-negotiable. Dehydration concentrates the calcium in the blood and can precipitate a hypercalcemic crisis. We educate every patient on the critical importance of drinking plenty of fluids, primarily water, throughout the day.
  • Dietary Calcium: A common misconception is that patients with high blood calcium should avoid dietary calcium. This is incorrect and counterproductive. Severely restricting calcium intake can actually stimulate the parathyroid glands further, worsening PTH production. We advise patients to consume a normal amount of dietary calcium, around 1000-1200 mg per day, primarily from food sources. We help them identify calcium-rich foods and create a balanced eating plan.
  • Limiting Supplemental Calcium: While dietary calcium is encouraged, over-the-counter calcium supplements should be avoided unless specifically prescribed and monitored.

Clinical Case Studies in Primary Hyperparathyroidism

Theory and research provide our foundation, but the real learning happens in the clinic, with real patients. I want to walk you through three distinct case studies from my practice. These examples showcase the varied presentations of primary hyperparathyroidism and the different paths we take for diagnosis and management, from surgical referral to complex medical management.

Case Study 1: The Cardiac Patient with Surprising Relief

This first case highlights how co-existing medical conditions can easily mask the symptoms of hyperparathyroidism, and how co-existing conditions can sometimes lead to unexpected improvements.

Patient Presentation

I was referred a 68-year-old Caucasian male by his cardiologist due to an abnormal lab result. His parathyroid hormone (PTH) level was 190 pg/mL.

• Past Medical History: His history was significant and complex, dominated by cardiovascular issues. He had non-obstructive coronary artery disease, non-ischemic cardiomyopathy, chronic systolic heart failure, and atrial fibrillation. Critically, he was not taking any Vitamin D supplements.
• Review of Systems: When he came to my office, his primary complaint was a vague sense of muscle achiness. Otherwise, he denied the classic hypercalcemia symptoms. Given his severe heart failure, one would naturally attribute any fatigue to his cardiac condition.

Diagnostic Workup

• Initial Labs: His CMP confirmed an elevated serum calcium of 8 mg/dL. His PTH was re-checked and remained high at 158 pg/mL. His 25-hydroxyvitamin D level was low at 16.3 ng/mL. A 24-hour urine calcium collection was significantly elevated at 364 mg/24 hours.
• Imaging Studies: A neck ultrasound identified a nodule measuring 12 x 20 x 11 mm that was highly suspicious for a parathyroid adenoma.

Surgical Intervention and Outcome

Based on these findings—symptomatic hypercalcemia, low Vitamin D, high 24-hour urine calcium, and a clearly identified adenoma—the decision was made to refer him for surgery. The surgery took place in April of 2024.

• Surgical Findings: The surgeon found and removed a left superior parathyroid adenoma.
• Intraoperative PTH Monitoring: PTH levels dropped rapidly from a baseline of 533 pg/mL to 42 pg/mL just 15 minutes after removal, confirming a successful surgery.

Postoperative Follow-Up

When I saw the patient back for his follow-up, he reported he felt better immediately after surgery. He had a significant improvement in his energy level and stamina and was even able to play golf again. His postoperative labs showed his serum calcium had normalized to 9.4 mg/dL. This case teaches us not to dismiss vague symptoms like fatigue, even in the presence of other convincing explanations, and underscores that surgery can sometimes provide life-changing benefits.

Case Study 2: Medical Management in a Complex Elderly Patient

This next case is one of the most interesting and clinically challenging I have managed. It illustrates the complexities of non-surgical management, especially in a frail, elderly patient with multiple comorbidities.

Patient Presentation

This patient is an 85-year-old Caucasian female whose journey with hyperparathyroidism began dramatically. She was brought to the emergency room with complaints of weakness and confusion.

• ER Visit and Hospital Course: In the ER, her calcium level was a dangerously high 8 mg/dL. This is considered a hypercalcemic crisis. She was treated aggressively with IV fluids, calcitonin, and an intravenous bisphosphonate (zoledronic acid). A malignancy workup was negative.
• Social and Medical History: The patient has chronic dementia. The family, considering her age and multiple medical issues, decided against surgery. The plan was for me to manage her calcium medically.

The Rollercoaster of Medical Management

Managing her calcium levels proved to be a significant challenge.

• January 2025: Her calcium climbed to 8 mg/dL. I started her on cinacalcet (Sensipar) at 30 mg once daily.
• The Downward Spiral: Shortly after, she became obtunded and was hospitalized again with a calcium of 8 mg/dL. She received another infusion of zoledronic acid.
• Escalating Therapy: After discharge, her calcium remained high. We increased her cinacalcet, but her calcium continued to climb.
• April 2026: Her calcium was 7 mg/dL, and she was on the maximum dose of cinacalcet: 90 mg twice a day. The medication was no longer effective on its own. The only remaining option was intermittent infusions of zoledronic acid.

Lessons Learned

This patient taught me some invaluable lessons. First, you cannot judge the severity of hypercalcemia by the patient’s clinical appearance. This pleasant, interactive 85-year-old woman was walking around with calcium levels that would have most people in a coma. Second, medical management is a valid option, especially when surgery is not feasible, but it is an intensive path. It requires frequent lab monitoring, vigilant patient and family education, and an unyielding focus on hydration.

Case Study 3: The Pilot with Foot Pain

This final case is a classic example of how surgery can resolve seemingly unrelated symptoms and lead to a complete biochemical cure.

Patient Presentation

A 57-year-old Caucasian male was referred to me for an elevated calcium of 10.5 mg/dL and a PTH of 111 pg/mL.

• Chief Complaint: For years, he had suffered from significant, chronic bilateral foot pain. He had seen several specialists, who had recommended complex foot surgeries, which he had declined.
• Past Medical History: He worked as a pilot. Importantly, he was already taking a high dose of Vitamin D, 5000 IU daily.

Diagnostic Workup

• Labs: His calcium was confirmed at 1 mg/dL, with a PTH of 84 pg/mL. His Vitamin D level was excellent at 43.2 ng/mL.
• Imaging Studies: A neck ultrasound was inconclusive. However, a renal ultrasound revealed an unexpected finding: a non-obstructing kidney stone on the left. The patient had been completely unaware of it.

The Decision for Surgery and a Surprising Outcome

The discovery of the asymptomatic kidney stone was a game-changer. The presence of nephrolithiasis is a firm indication for surgical intervention. He was referred to an experienced endocrine surgeon. The surgery took place in May of 2026, and the surgeon successfully located and removed a parathyroid adenoma.

When the patient returned for his follow-up visit with me in August, he was ecstatic. His chronic foot pain, which had plagued him for years, was so much better. This is a phenomenon I’ve seen several times. The diffuse “bone and joint aches” associated with hyperparathyroidism can manifest in specific, localized ways. For him, it was in his feet. His postoperative labs confirmed a complete cure, with a perfect calcium of 9.7 mg/dL and a normal PTH of 32 pg/mL. This case is a beautiful summary of how a clear diagnosis, a firm surgical indication, and a successful surgery can lead to complete biochemical resolution and the unexpected, welcome relief of long-standing symptoms.

A Final Anecdote

To end on a personal clinical note, I had a fascinating conversation with a patient today that speaks to the nuances of surgical recovery. He had undergone parathyroid surgery many years ago. He told me that when he woke up from the procedure, his voice was very hoarse and he had difficulty speaking. This was due to the surgeon stretching or irritating the recurrent laryngeal nerve, which controls the vocal cords, during the operation.

His surgeon’s follow-up was unique. Instead of having the patient come into the office, the surgeon called him at home every Friday for seven consecutive weeks. The patient said, “He would call me, and I would answer, and just by listening to me say hello and talk for a minute, he could tell how the nerve was recovering.” The surgeon would offer reassurance, saying, “It’ll get better, it’ll get better.” And sure enough, by the seventh week, his voice had returned completely to normal. This story, while from a different era of medicine, is a wonderful example of attentive, personalized follow-up and a reminder of the specific potential complications of this delicate neck surgery.

Hyperparathyroidism is a truly interesting condition, spanning from a silent biochemical abnormality to a life-altering systemic disease. I hope this detailed exploration has provided you with valuable knowledge and a clearer understanding of our integrative approach. If you have any questions, please do not hesitate to reach out. I am always glad to answer emails or provide further clarification. Thank you so much for joining me on this educational journey.

References

• Bilezikian, J. P., Bandeira, L., Khan, A., & Cusano, N. E. (2018). Hyperparathyroidism. The Lancet, 391(10116), 168–178.
• Bilezikian, J. P., Brandi, M. L., Eastell, R., Silverberg, S. J., Udelsman, R., Marcocci, C., & Potts, Jr., J. T. (2014). Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3561–3569.
• Bilezikian, J. P., Meng, X., Shi, Y., & Silverberg, S. J. (2000). Primary hyperparathyroidism in women: a tale of two cities–New York and Beijing. The Journal of Clinical Endocrinology & Metabolism, 85(11), 4078-4083.
• Eastell, R., Brandi, M. L., Costa, A. G., D’Amour, P., Shoback, D. M., & Thakker, R. V. (2014). Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3570–3579.
• Holick, M. F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281.
• Khan, A. A., Hanley, D. A., Rizzoli, R., Bollerslev, J., Young, J. E., Rejnmark, L., … & Bilezikian, J. P. (2017). Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporosis International, 28(1), 1–19.
• Lee, J. Y., & Kim, S. W. (2015). A practical approach to hypercalcemia. Endocrinology and Metabolism, 30(3), 256–262.
• Marx, S. J. (2000). Hyperparathyroid and hypoparathyroid disorders. New England Journal of Medicine, 343(25), 1863–1875.
• Peacock, M., Bilezikian, J. P., Bolognese, M. A., Borofsky, M., Scumpia, S., & Sterling, L. R. (2005). Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 90(1), 135–141.
• Pretorius, M., Lundstam, K., Heck, A., Fagerland, M. W., Godang, K., Mollerup, C., … & Bollerslev, J. (2020). Effect of parathyroidectomy on quality of life in asymptomatic primary hyperparathyroidism: a 10-year follow-up of a prospective randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 105(4), dgz242.
• Silverberg, S. J., Clarke, B. L., Peacock, M., Bandeira, F., Boutroy, S., Cusano, N. E., … & Bilezikian, J. P. (2014). The diagnosis of normocalcemic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3654–3660.
• Silverberg, S. J., Shane, E., Jacobs, T. P., Siris, E., & Bilezikian, J. P. (2000). A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New England Journal of Medicine, 341(17), 1249-1255.
• Udelsman, R., Åkerström, G., Biagini, C., Duh, Q. Y., Miccoli, P., Tassone, F., & Hamberger, B. (2014). The surgical management of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3595–3606.
• Walker, M. D., & Silverberg, S. J. (2018). Primary hyperparathyroidism. Nature Reviews Endocrinology, 14(2), 115–125.

SEO Tags: hyperparathyroidism, hypercalcemia, high calcium, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, integrative medicine, functional medicine, chiropractic, El Paso TX, parathyroid hormone, PTH, DEXA scan, parathyroidectomy, kidney stones, osteoporosis, vitamin D deficiency, Cinacalcet, Sensipar, primary hyperparathyroidism, secondary hyperparathyroidism, normocalcemic hyperparathyroidism, bone health, endocrine disorders, injury medical clinic, multidisciplinary care, parathyroid adenoma, sestamibi scan, zoledronic acid, bone density, osteitis fibrosa cystica, quality of life, asymptomatic hyperparathyroidism, medical management, endocrine surgery, musculoskeletal pain, vertebral subluxation, holistic healthcare